The FDA found “unacceptable levels” of a cancer-causing impurity in limited testing using low-heat method of samples of heartburn medicines such as Zantac containing the ingredient ranitidine.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Johnson & Johnson will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation’s opioid epidemic.
Eight drug companies urged a federal appeals court to disqualify the judge overseeing nationwide opioid litigation, in a last-ditch effort to avoid having him preside over a landmark trial.
In the wake of the discovery that some Zantac products may contain a carcinogen contaminant due to the manufacturing process, drug store retailers removed the antacid from shelves.
Shares of Dova Pharmaceuticals were up more than 38 percent after Sweden-based Sobi announced the intended acquisition of the North Carolina-based company for $915 million.
Ian Read, a stalwart figure at Pfizer for four decades, will step down from his role as executive chairman of the board of directors at the end of 2019.
U.S. federal agents executed a warrant to search the Clio Laboratories in Georgia as part of a nationwide crackdown into genetic testing fraud against federal health insurance programs.
Mylan NV agreed to settle U.S. SEC charges that the company hid from investors the impact of a federal probe into the drugmaker’s overbilling the government for the EpiPen allergy treatment.
A U.S. House panel sent letters to four e-cigarette companies asking them to stop all print, broadcast and digital advertising of their products in the United States.
Juul Labs said the company would suspend all broadcast, print and digital product advertising in the United States and replaced CEO Kevin Burns.